Answers are grounded in this paper and cite their sources.
Revumenib, an oral, small molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a phase I study of heavily pretreated patients with
No takes yet. Share an insight, caveat, or question.
Issa et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: